Vagal afferent-dependent cholecystokinin modulation of visceral pain requires central amygdala NMDA-NR2B receptors in rats

Neurogastroenterology and Motility

Volumn 27, Issue 9, 2015, Pages 1333-1343

  Wang, E M ^a   Li, W T ^a   Yan, X J ^a   Chen, X ^a   Liu, Q ^a   Feng, C C ^a   Cao, Z J ^a   Fang, J Y ^a   Chen, Sheng Liang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Cholecystokinin; NR2B receptors; The central amygdala; Vagal afferents; Visceral pain

Indexed keywords

CAPSAICIN; CHOLECYSTOKININ A RECEPTOR; CHOLECYSTOKININ OCTAPEPTIDE; DEVAZEPIDE; DIZOCILPINE; IFENPRODIL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; PROTEIN C FOS; SMALL INTERFERING RNA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NR2B NMDA RECEPTOR; PIPERIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CENTRAL NUCLEUS (AMYGDALA); COLORECTAL DISEASE; COLORECTAL DISTENTION; CONTROLLED STUDY; DEAFFERENTATION; ELECTROPORATION; HISTOLOGY; IRRITABLE COLON; MALE; MOTOR PERFORMANCE; NOCICEPTION; NODOSE GANGLION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; STEREOTAXIC SURGERY; VAGOTOMY; VAGUS NERVE; VISCERAL PAIN; VISCEROMOTOR RESPONSE; WESTERN BLOTTING; ABDOMINAL WALL MUSCULATURE; AGONISTS; ANIMAL; DRUG EFFECTS; HYPERALGESIA; METABOLISM; PAIN MEASUREMENT; PATHOPHYSIOLOGY; PHOSPHORYLATION; PHYSIOLOGY; SENSORY NERVE; SPRAGUE DAWLEY RAT;

ABDOMINAL MUSCLES; AFFERENT PATHWAYS; ANIMALS; CENTRAL AMYGDALOID NUCLEUS; HYPERALGESIA; MALE; NOCICEPTION; PAIN MEASUREMENT; PHOSPHORYLATION; PIPERIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, N-METHYL-D-ASPARTATE; SINCALIDE; VAGOTOMY; VAGUS NERVE; VISCERAL PAIN;

EID: 84939773613     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/nmo.12633     Document Type: Article

References (51)

1. Zhou Q, Verne GN. New insights into visceral hypersensitivity{box drawings light horizontal}clinical implications in IBS. Nat Rev Gastroenterol Hepatol 2011; 8: 349-55.
2. Simrén M, Abrahamsson H, Björnsson ES. An exaggerated sensory component of the gastrocolonic response in patients with irritable bowel syndrome. Gut 2001; 48: 20-7.
3. Simrén M, Agerforz P, Björnsson ES, Abrahamsson H. Nutrient-dependent enhancement of rectal sensitivity in irritable bowel syndrome (IBS). Neurogastroenterol Motil 2007; 19: 20-9.
4. Caldarella MP, Milano A, Laterza F, Sacco F, Balatsinou C, Lapenna D, Pierdomenico SD, Cuccurullo F et al. Visceral sensitivity and symptoms in patients with constipation- or diarrhea-predominant irritable bowel syndrome (IBS): effect of a low-fat intraduodenal infusion. Am J Gastroenterol 2005; 100: 383-9.
5. Liddle RA, Goldfine ID, Rosen MS, Taplitz RA, Williams JA. Cholecystokinin bioactivity in human plasma. Molecular forms, responses to feeding, and relationship to gallbladder contraction. J Clin Invest 1985; 75: 1144-52.
6. Feinle C, Christen M, Grundy D, Faas H, Meier O, Otto B, Fried M. Effects of duodenal fat, protein or mixed-nutrient infusions on epigastric sensations during sustained gastric distension in healthy humans. Neurogastroenterol Motil 2002; 14: 205-13.
7. Cremonini F, Camilleri M, McKinzie S, Carlson P, Camilleri CE, Burton D, Thomforde G, Urrutia R et al. Effect of CCK-1 antagonist, dexloxiglumide, in female patients with irritable bowel syndrome: a pharmacodynamic and pharmacogenomic study. Am J Gastroenterol 2005; 100: 652-63.
8. Sabaté JM, Gorbatchef C, Flourié B, Jian R, Coffin B. Cholecystokinin octapeptide increases rectal sensitivity to pain in healthy subjects. Neurogastroenterol Motil 2002; 14: 689-95.
9. van der Schaar PJ, van Hoboken E, Ludidi S, Masclee AA. Effect of cholecystokinin on rectal motor and sensory function in patients with irritable bowel syndrome and healthy controls. Colorectal Dis 2013; 15: e29-34.
10. Passaro E Jr, Debas H, Oldendorf W, Yamada T. Rapid appearance of intraventricularly administered neuropeptides in the peripheral circulation. Brain Res 1982; 241: 335-40.
11. Zhu XG, Greeley GH Jr, Lewis BG, Lilja P, Thompson JC. Blood-CSF barrier to CCK and effect of centrally administered bombesin on release of brain CCK. J Neurosci Res 1986; 15: 393-403.
12. Raybould HE, Taché Y. Cholecystokinin inhibits gastric motility and emptying via a capsaicin-sensitive vagal pathway in rats. Am J Physiol 1988; 255: G242-6.
13. Neugebauer V, Li W, Bird GC, Han JS. The amygdala and persistent pain. Neuroscientist 2004; 10: 221-34.
14. Tillisch K, Mayer EA, Labus JS. Quantitative meta-analysis identifies brain regions activated during rectal distension in irritable bowel syndrome. Gastroenterology 2011; 140: 91-100.
15. Ricardo JA, Koh ET. Anatomical evidence of direct projections from the nucleus of the solitary tract to the hypothalamus, amygdala, and other forebrain structures in the rat. Brain Res 1978; 153: 1-26.
16. Zardetto-Smith AM, Gray TS. Organization of peptidergic and catecholaminergic efferents from the nucleus of the solitary tract to the rat amygdala. Brain Res Bull 1990; 25: 875-87.
17. Myers EA, Rinaman L. Viscerosensory activation of noradrenergic inputs to the amygdala in rats. Physiol Behav 2002; 77: 723-9.
18. Li W, Neugebauer V. Block of NMDA and non-NMDA receptor activation results in reduced background and evoked activity of central amygdala neurons in a model of arthritic pain. Pain 2004; 110: 112-22.
19. Ji G, Horváth C, Neugebauer V. NR2B receptor blockade inhibits pain-related sensitization of amygdala neurons. Mol Pain 2009; 5: 21.
20. Spuz CA, Borszcz GS. NMDA or non-NMDA receptor antagonism within the amygdaloid central nucleus suppresses the affective dimension of pain in rats: evidence for hemispheric synergy. J Pain 2012; 13: 328-37.
21. Lopez de Armentia M, Sah P. Development and subunit composition of synaptic NMDA receptors in the amygdala: NR2B synapses in the adult central amygdala. J Neurosci 2003; 23: 6876-83.
22. Yan XJ, Feng CC, Liu Q, Zhang LY, Dong X, Liu ZL, Cao ZJ, Mo JZ et al. Vagal afferents mediate antinociception of estrogen in a rat model of visceral pain: the involvement of intestinal mucosal mast cells and 5-hydroxytryptamine 3 signaling. J Pain 2014; 15: 204-17.
23. Blackshaw LA, Page AJ, Partosoedarso ER. Acute effects of capsaicin on gastrointestinal vagal afferents. Neuroscience 2000; 96: 407-16.
24. Zafra MA, Molina F, Puerto A. Effects of perivagal administration of capsaicin on post-surgical food intake. Auton Neurosci 2003; 107: 37-44.
25. Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates. 3rd edn. San Diego: Academic Press, 1997.
26. 3 receptors in a rat model of delayed stress-induced visceral hyperalgesia. Pain 2007; 130: 56-65.
27. Rehfeld JF, Sun G, Christensen T, Hillingsø JG. The predominant cholecystokinin in human plasma and intestine is cholecystokinin-33. J Clin Endocrinol Metab 2001; 86: 251-8.
28. Rehfeld JF, Friis-Hansen L, Goetze JP, Hansen TV. The biology of cholecystokinin and gastrin peptides. Curr Top Med Chem 2007; 7: 1154-65.
29. Campos CA, Wright JS, Czaja K, Ritter RC. CCK-induced reduction of food intake and hindbrain MAPK signaling are mediated by NMDA receptor activation. Endocrinology 2012; 153: 2633-46.
30. Skovira JW, McDonough JH, Shih TM. Protection against sarin-induced seizures in rats by direct brain microinjection of scopolamine, midazolam or MK-801. J Mol Neurosci 2010; 40: 56-62.
31. Sotres-Bayon F, Bush DE, LeDoux JE. Acquisition of fear extinction requires activation of NR2B-containing NMDA receptors in the lateral amygdala. Neuropsychopharmacology 2007; 32: 1929-40.
32. Walker DL, Davis M. Amygdala infusions of an NR2B-selective or an NR2A-preferring NMDA receptor antagonist differentially influence fear conditioning and expression in the fear-potentiated startle test. Learn Mem 2008; 15: 67-74.
33. Zhao MG, Toyoda H, Lee YS, Wu LJ, Ko SW, Zhang XH, Jia Y, Shum F et al. Roles of NMDA NR2B subtype receptor in prefrontal long-term potentiation and contextual fear memory. Neuron 2005; 47: 859-72.
34. Fan J, Wu X, Cao Z, Chen S, Owyang C, Li Y. Up-regulation of anterior cingulate cortex NR2B receptors contributes to visceral pain responses in rats. Gastroenterology 2009; 136: 1732-40.e3.
35. Nakazawa T, Komai S, Tezuka T, Hisatsune C, Umemori H, Semba K, Mishina M, Manabe T et al. Characterization of Fyn-mediated tyrosine phosphorylation sites on GluR epsilon 2 (NR2B) subunit of the N-methyl-d-aspartate receptor. J Biol Chem 2001; 276: 693-9.
36. Chen BS, Roche KW. Regulation of NMDA receptors by phosphorylation. Neuropharmacology 2007; 53: 362-8.
37. Peters JH, Ritter RC, Simasko SM. Leptin and CCK selectively activate vagal afferent neurons innervating the stomach and duodenum. Am J Physiol Regul Integr Comp Physiol 2006; 290: R1544-9.
38. Friedrich AE, Gebhart GF. Modulation of visceral hyperalgesia by morphine and cholecystokinin from the rat rostroventral medial medulla. Pain 2003; 104: 93-101.
39. Heinricher MM, Neubert MJ. Neural basis for the hyperalgesic action of cholecystokinin in the rostral ventromedial medulla. J Neurophysiol 2004; 92: 1982-9.
40. Kim J, Kim JH, Kim Y, Cho HY, Hong SK, Yoon YW. Role of spinal cholecystokinin in neuropathic pain after spinal cord hemisection in rats. Neurosci Lett 2009; 462: 303-7.
41. Cao B, Zhang X, Yan N, Chen S, Li Y. Cholecystokinin enhances visceral pain-related affective memory via vagal afferent pathway in rats. Mol Brain 2012; 5: 19.
42. 1 pathway. Am J Physiol Regul Integr Comp Physiol 2004; 287: R354-9.
43. Moran TH, Kornbluh R, Moore K, Schwartz GJ. Cholecystokinin inhibits gastric emptying and contracts the pyloric sphincter in rats by interacting with low affinity CCK receptor sites. Regul Pept 1994; 52: 165-72.
44. Broberger C, Holmberg K, Shi TJ, Dockray G, Hökfelt T. Expression and regulation of cholecystokinin and cholecystokinin receptors in rat nodose and dorsal root ganglia. Brain Res 2001; 903: 128-40.
45. Simasko SM, Wiens J, Karpiel A, Covasa M, Ritter RC. Cholecystokinin increases cytosolic calcium in a subpopulation of cultured vagal afferent neurons. Am J Physiol Regul Integr Comp Physiol 2002; 283: R1303-13.
46. Browning KN, Babic T, Holmes GM, Swartz E, Travagli RA. A critical re-evaluation of the specificity of action of perivagal capsaicin. J Physiol 2013; 591: 1563-80.
47. Cottrell GT, Ferguson AV. Sensory circumventricular organs: central roles in integrated autonomic regulation. Regul Pept 2004; 117: 11-23.
48. Sun K, Ferguson AV. Cholecystokinin activates area postrema neurons in rat brain slices. Am J Physiol 1997; 272: R1625-30.
49. Grundy D. Neuroanatomy of visceral nociception: vagal and splanchnic afferent. Gut 2002; 51: i2-5.
50. Andrews PL, Sanger GJ. Abdominal vagal afferent neurones: an important target for the treatment of gastrointestinal dysfunction. Curr Opin Pharmacol 2002; 2: 650-6.
51. Sjölund K, Ekman R, Lindgren S, Rehfeld JF. Disturbed motilin and cholecystokinin release in the irritable bowel syndrome. Scand J Gastroenterol 1996; 31: 1110-4.